What is Zacks Research’s Estimate for CPRX Q3 Earnings?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Investment analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for shares of Catalyst Pharmaceuticals in a research report issued on Wednesday, March 18th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $0.64 per share for the quarter, up from their previous forecast of $0.59. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q3 2027 earnings at $0.69 EPS and FY2028 earnings at $3.00 EPS.

Several other analysts also recently weighed in on CPRX. Weiss Ratings reissued a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Monday, December 29th. Citigroup raised their price target on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $34.00.

Catalyst Pharmaceuticals Stock Up 2.1%

Shares of Catalyst Pharmaceuticals stock opened at $22.79 on Friday. The firm has a market capitalization of $2.78 billion, a P/E ratio of 13.49, a PEG ratio of 0.66 and a beta of 0.75. The company has a 50 day moving average price of $23.95 and a 200 day moving average price of $22.56. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $26.58.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CPRX. Hsbc Holdings PLC lifted its holdings in Catalyst Pharmaceuticals by 91.9% in the fourth quarter. Hsbc Holdings PLC now owns 57,929 shares of the biopharmaceutical company’s stock valued at $1,362,000 after acquiring an additional 27,739 shares during the period. Rockefeller Capital Management L.P. grew its stake in shares of Catalyst Pharmaceuticals by 29.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 29,680 shares of the biopharmaceutical company’s stock worth $693,000 after purchasing an additional 6,752 shares during the period. Invesco Ltd. increased its holdings in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Invesco Ltd. now owns 1,293,478 shares of the biopharmaceutical company’s stock valued at $30,190,000 after purchasing an additional 60,221 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $630,000. Finally, Mackenzie Financial Corp acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $210,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).